Laboratory and Epidemiology Communications

Leukocytopenia due to Zidovudine- and Nevirapine-Containing Regimens in Elderly Patients with HIV Infection

Yoshihiko Yamamoto1,2, Akira Yasuoka1, Chie Yasuoka1, Ikumi Genka1, Katsushi Teruya1, Yoshimi Kikuchi1, Natsuo Tachikawa1 and Shinichi Oka1*

1AIDS Clinical Center, International Medical Center of Japan, Toyama 1-21-1, Shinjuku-ku, Tokyo 162-8655 and 2The Organization for Pharmaceutical Safety and Research of Japan, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013

Communicated by Hiroshi Yoshikura
(Accepted December 28, 2000)

Leukocytopenia was observed in three cases among 17 HIV-1-infected patients receiving regimens containing both zidovudine (ZDV) and nevirapine (NVP) (Table). Common features included the occurrence of leukocytopenia within 5 weeks of treatment, good response to granulocyte-colony stimulating factor (G-CSF), and the advanced age of the patients. In two of the patients, leukocytopenia was absent during regimens containing either ZDV or NVP alone.

Case 1: A 48-year-old HIV-1-infected homosexual man commenced highly active antiretroviral therapy (HAART) with ZDV/NVP/lamivudine (3TC) on January 11, 1999. Two weeks later, the dose of NVP was raised to 400 mg/day. At that time, WBC was 3,800/μL, CD4 count 263/μL, and viral load 700 copies/ml. On February 13, 1999, 33 days of the therapy, he developed diarrhea, fever (40°C), and impetigo on his back. As leukocytopenia (240/μL; neutrophil 0%) was noted, he was hospitalized. HAART was stopped immediately, and subcutaneous administration of G-CSF at a dose of 300 μg daily was started. Both pyrexia and diarrhea improved within 9 days. WBC recovered to 6,200/μL within 3 days. A new regimen containing stavudine (d4T)/NVP/3TC was then begun. No further episodes of leukocytopenia occurred subsequently.

Case 2: A 68-year-old HIV-1-infected homosexual man was admitted to our hospital due to the onset of Pneumocystis carinii pneumonia (PCP) on September 16, 1999. After treatment of PCP, he commenced HAART, which included ZDV/NVP/ritonavir on November 19, 1999. At that time, WBC was 3,500/μL, CD4 count 2/μL, and the viral load 610,000 copies/ml. Twenty-three days later, his body temperature rose to 39°C. As WBC decreased to 200/μL, HAART was stopped. Subcutaneous administration of G-CSF at 300 μg daily was initiated on December 12. The nadir WBC was 70/μL (neutrophil 1%) on December 16. Although WBC recovered to 2,070/μL and body temperature returned to normal on December 22, the patient died of disseminated candidiasis on February 3, 2000. In this case, transient thrombocytopenia with a nadir count of 5,000/μL was observed on December 18.

Case 3: A 50-year-old HIV-1-infected hemophiliac had been treated with ZDV/didanosine (ddI) since 1996; ritonavir/saquinavir (RTV/SQV) were added to the regimen in January 1999. Although he showed an excellent response to this regimen, achieving suppression of viral load to below quantifiable levels and an elevation of the CD4 count to more than 500/μL, he complained of exacerbation of hemophiliac arthritis associated with more frequent bleeding episodes after adding RTV/SQV. Therefore, RTV/SQV were replaced by NVP at 200 mg/day on January 18, 2000, and the dose of NVP was increased to 400 mg/day on February 6. However, WBC declined from 4,900/μL to 1,000/μL (neutrophil 50%) on February 10. HAART was stopped, and G-CSF was given subcutaneously for 4 days at a dose of 150 μg daily. WBC recovered to 5,500/μL on February 15. Twenty days later, HAART was re-initiated with d4T/3TC/efavirenz. No further episodes of leukocytopenia were experienced.

The incidence of AIDS and mortality due to AIDS have

<table>
<thead>
<tr>
<th>case</th>
<th>age (year)</th>
<th>prior regimen</th>
<th>drug other than ZDV/NVP</th>
<th>WBC (μL) before</th>
<th>nadir (neutrophil %)</th>
<th>days after commencement</th>
<th>alternative therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>none</td>
<td>3TC</td>
<td>3,800</td>
<td>246 (0%)</td>
<td>33</td>
<td>d4T/3TC/NVP</td>
</tr>
<tr>
<td>2</td>
<td>68</td>
<td>none</td>
<td>NFV</td>
<td>3,500</td>
<td>70 (1%)</td>
<td>23</td>
<td>none</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>ZDV/ddI/RTV/SQV</td>
<td>ddI</td>
<td>4,900</td>
<td>1000 (50%)</td>
<td>24</td>
<td>d4T/3TC/EFV</td>
</tr>
</tbody>
</table>


*Corresponding author: Tel/Fax: +81-3-5273-5193, E-mail: oka@imej.hosp.go.jp
been declining markedly in the era of HAART, which includes the use of two nucleoside reverse-transcriptase inhibitors (NRTIs) and an HIV-specific protease inhibitor (PI). However, adherence to these regimens is often difficult because of the large number of pills, side effects, and drug-drug interactions related to PIs. Furthermore, reports of unexpected serious side effects in patients exposed to PIs over a long period are increasing in number. In particular, metabolic disturbances such as increased levels of cholesterol or triglycerides and insulin-resistant diabetes in association with abnormal fat redistribution, which is referred to as lipodystrophy syndrome (1), have been observed. Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are advantageous due to the lower burden of pills and fewer drug-drug interactions compared with PI. Therefore, HAART consisting of 2 NRTIs and 1 NNRTI is being prescribed as initial therapy in treatment-naive patients, and ‘switch therapy’ with NVP in place of PIs is being prescribed for patients with long-term sustained viral suppression (2). Leukopenia caused by ZDV was reported soon after its approval (3). However, there has been little information regarding myelotoxicity caused by antiretroviral regimens containing NVP in adults. At our hospital, 44 patients have been treated with NVP-containing regimens since 1997. Seventeen underwent regimens containing NVP and ZDV. As described above, 3 out of 17 patients (17.6%) developed leukopenia 3-5 weeks after the commencement of antiretroviral therapy. In cases 1 and 2, regimens including ZDV and NVP were introduced as the first antiretroviral therapy, resulting in leukopenia. In case 1, ZDV was replaced by d4T, while 3TC and NVP were not changed in the second regimen, this patient had no further episodes of leukopenia. Although case 3 had been treated with ZDV/ddI since 1996, he had never developed leukopenia until dual-PIs were changed to NVP. These observations appear to indicate that leukopenia by ZDV might be intensified by NVP.

Toxic hepatitis and Stevens-Johnson's syndrome have been reported as serious adverse events associated with NVP. However, in previous studies of NVP in combination with ZDV, serious leukopenia has not been reported among the more than 400 participants studied (4). In our cases, the patients were relatively older. If advanced age is a predisposing factor for leukopenia, this will have clinical relevance. Lipodystrophy syndrome can cause cardiovascular complications (5). Therefore, older patients should likely be given PI-sparing regimens to avoid complications. Our observations appear to suggest that the myelotoxicity of ZDV can be exacerbated by NVP. It may therefore be important to be aware of this potential side effect, especially during the first 5 weeks of therapy in elderly patients.

This study was supported by grants from the Ministry of Health and Welfare of Japan, and the Organization for Pharmaceutical Safety and Research (OPSR) of Japan.

REFERENCES


